At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 57 enrolled
Drug / intervention
Iopamidol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin as New Biomarker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320
In Brief
A Phase 4 clinical trial evaluating Iopamidol and Iodixanol-320 for Coronary Artery Stenosis. Completed, enrolled 57 participants across 4 sites in 2 countries.
Detailed Summary
To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Stenosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartNov 2010
Primary CompletionNov 2012
TodayJul 2026
First PostedJun 4, 2010
Enrollment StartNov 1, 2010
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.1 years ago
Interventions
Iopamidoldrug
Iopamidol 370, one time administration for percutaneous coronary intervention
Iodixanol-320drug
Iodixanol-320 single administration for percutaneous coronary intervention procedure